Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole safety study in adolescents with clinically diagnosed GERD
2012-001136-61Phase 3
- Sponsor
- AstraZeneca
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esomeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Primary safety endpoint.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2012-001136-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001136-61.